Hodgkin lymphoma: answers take time!

Friedberg, Jonathan W.

doi:10.1182/blood-2011-03-340307

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, up to 30% and 10% of patients will recur and die of HL in advanced and early disease respectively, and unlike what happened in non Hodgkin lymphomas, newer active compounds against HL have not been introduced in clinic since the early 1970s. In addition, patients exposed to chemotherapy and radiation fields are at highest risk of lethal second malignancies (Friedberg, 2011). Therefore it would be more than desirable having new therapeutic drugs and strategies for a better control of the disease and minimizing toxicity of therapy, especially when relapses occur.…”

Section: Antineoplastic Therapy In Hl: From Classical To Biological Tmentioning

confidence: 99%

“…Some strategies, in particular radioimmunotherapeutic approaches and immunotoxins have already shown significant effectivity (Friedberg, 2011). First experiences with relatively non-toxic immunomodulatory compounds have implemented a whole new kind of immunotherapy in NLPHL where the anti-CD20-antibody Rituximab might be the future effective but less toxic treatment (Ekstrand et al, 2003;Schulz et al, 2008).…”

Section: Body's Own Power Protection Challenges In Hlmentioning

confidence: 99%

See 1 more Smart Citation

Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

Lejeune¹,

Cruz‐Merino²,

Álvaro³

2012

Hodgkin's Lymphoma

View full text Add to dashboard Cite

Section: Antineoplastic Therapy In Hl: From Classical To Biological Tmentioning

confidence: 99%

Section: Body's Own Power Protection Challenges In Hlmentioning

confidence: 99%

Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

Lejeune¹,

Cruz‐Merino²,

Álvaro³

2012

Hodgkin's Lymphoma

View full text Add to dashboard Cite

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma

Kobe

Kuhnert

Kahraman

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy

2016

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar immunodeficiency and manifestations while they are not covered by the current IVIg indications. A potential beneficial strategy could be to vaccinate patients at monoclonal B lymphocytosis and monoclonal gammopathy of undetermined significance stages (for CLL and MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are attained. We have to re-emphasize the need for assessing and monitoring specific antibody responses; these are warranted to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review provides an overview of the current scenario, with a focus on prevention of infection in patients with hematological malignancies and the role of Ig replacement therapy.

show abstract

Hodgkin lymphoma: answers take time!

Cited by 3 publications

References 9 publications

Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy

Contact Info

Product

Resources

About